Influenza Diagnostics Market

Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026

Report Code: MD 7514 Sep, 2021, by marketsandmarkets.com

[193 Pages Report] The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7%. Market growth is driven by rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies.

Influenza Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Influenza Diagnostics Market

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The COVID-19 pandemic has significantly affected the influenza diagnostics market; unfavorable changes in regulations and guidelines, the closing of manufacturing facilities due to lockdowns and disruptions in supply chains have severely affected the market growth. In addition, limited operations in most industries, inadequate funding for research and academic institutes, and challenges in providing essential/post-sales services due to lockdowns have reduced the supply of influenza diagnostics products to end users. Furthermore, there are many similarities between influenza and COVID-19; both seasonal flu (influenza A and B) and COVID-19 are contagious viruses and show similar symptoms of respiratory illness. Influenza outbreaks generally occur from December to February. The COVID-19 outbreak also occurred during the influenza season, resulting in the increased adoption of influenza tests during this period.

Despite the challenging situation, industries are gradually recovering from the impact, and supply and distribution channels have also resumed.

Market Dynamics

Driver: Growth in influenza research for diagnostic technologies

The rising prevalence of influenza across the globe has increased R&D efforts towards its effective detection and diagnosis. Most research activity focuses on developing faster and more accurate diagnostic solutions for influenza viruses leading to market growth.

Opportunity: Advancements in genomic and proteomic technologies

The Human Genome Project and advances in molecular and biomedical technologies have generated a vast amount of data, which have resulted in the development of a multitude of assays and technologies useful for the diagnosis and management of influenza infections. These new technologies, based on genomic techniques (such as PCR-based) and proteomics (such as microarray-based detection), help discover new influenza viruses. They also enable better surveillance and rapid diagnosis of infectious diseases which serves as an opportunity for the market.

Restraint: Variabilities in test sensitivity and specificity

Sensitivity and specificity are the major factors that impact the results of influenza diagnostic tests. The antigenic variation of influenza viruses is the main reason behind the complexity of these tests. As a result, variabilities exist in the sensitivity and specificity of influenza diagnostic tests, which can impact the final test results. Due to this factor, false-negative results are more common than false-positive results, especially during peak influenza season which is a major factor restraining the growth of the influenza diagnostics market.

Challenge: Stringent regulatory framework

A major challenge that most diagnostic companies face in commercializing their tests is getting Medicare and private health insurers to pay for them. This is important not only to help the decision-making process of physicians within the practice of evidence-based medicine but also to achieve regulatory approvals and reimbursements for the tests. Regulatory approvals for influenza tests have become more stringent in recent years to ensure their efficiency in detecting all types of influenza viruses.

In 2020, test kits and reagents segment accounted for the largest share of the influenza diagnostics market, by product

The influenza diagnostics market is segmented into test kits and reagents, instruments and other products based on product. The test kits and reagents segment accounted for the largest share of the influenza diagnostics market in 2020, mainly due to the increase increasing prevalence of influenza and rising demand of rapid disease diagnosis.

In 2020, molecular diagnostic tests segment accounted for the largest share of the influenza diagnostics market, by test type

The influenza diagnostics market is segmented into molecular diagnostics tests and traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the largest share. Factors such as growth in influenza research for diagnostic technologies and increasing prevalence of influenza drive this market.

In 2020, diagnostic laboratories segment accounted for the largest share in the influenza diagnostics market, by end users

The influenza diagnostics market has been segmented into diagnostic laboratories, hospitals and clinics and other end users based on end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis is driving the growth of this segment.

North America is the largest regional market for influenza diagnostics market

The global influenza diagnostics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global influenza diagnostics market. The North American influenza diagnostics market's growth can be attributed to the growth in influenza research for diagnostic technologies and increasing prevalence of influenza.

Influenza Diagnostics Market  by Region

Some key players in the influenza diagnostics market (2021- 2026)

  • Thermo Fisher Scientific, Inc. (US
  • Becton, Dickinson and Company (US)
  • F. Hoffmann-LA Roche AG (Switzerland)
  • Hologic, Inc. (US)
  • Abbott Laboratories, Inc. (Us)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product, test type, end user and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecan Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada), Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India)

This report categorizes the influenza diagnostics market into the following segments and subsegments:

By Product

  • Test Kit and Reagents
  • Instruments
  • Other Prodcuts

By Test Type

  • Molecular Diagnostic Tests
    • Polymerase Chain Reaction
    • Isothermal Nucleic Acid Amplification Tests
  • Transcription-Mediated Amplification-Based Assay
  • Loop-Mediated Isothermal Amplification-Based Assay
  • Nucleic Acid Sequence-Based Amplification Tests
  • Other Isothermal Nucleic Acid Amplification Tests
    • Other Molecular Tests
  • Traditional Diagnostic Tests
    • Rapid Influenza Diagnostic Tests
    • Viral Culture Tests
    • Direct Fluorescent Antibody Test
    • Serological Tests

By End User

  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Other End users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In May 2021 Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which is used to detect SARS-CoV-2, influenza A, and influenza B.
  • In March 2021, Abbott Laboratories, Inc. (US) received emergency use authorization (EUA) from the FDA for a laboratory PCR assay that detects and differentiates SARS-COV-2, flu A, flu B, and RSV in one test.
  • In February 2021, Becton, Dickinson and Company (US) received approval from the FDA for the emergency use authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and influenza A+B.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
                    FIGURE 1 INFLUENZA DIAGNOSTICS MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 2 INFLUENZA DIAGNOSTICS MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Key industry insights
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    FIGURE 4 INFLUENZA DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
                    FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 INFLUENZA DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 GROWTH RATE ASSUMPTIONS
    2.7 LIMITATIONS
    2.8 RISK ASSESSMENT
    2.9 COVID-19 HEALTH ASSESSMENT
    2.10 COVID-19 ECONOMIC ASSESSMENT
    2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 10 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 INFLUENZA DIAGNOSTICS MARKET OVERVIEW
           FIGURE 14 INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH
    4.2 INFLUENZA DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021 VS. 2026
           FIGURE 15 TEST KITS & REAGENTS WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.3 INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2021 VS. 2026
           FIGURE 16 MOLECULAR DIAGNOSTIC TESTS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.4 INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 17 DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF THE INFLUENZA DIAGNOSTICS MARKET
    4.5 INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 NORTH AMERICA TO COMMAND THE LARGEST SHARE AND ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE INFLUENZA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of influenza
                    5.2.1.2 Growth in influenza research for diagnostic technologies
                    5.2.1.3 Rising demand for rapid disease diagnosis
           5.2.2 RESTRAINTS
                    5.2.2.1 Variabilities in test sensitivity and specificity
                    5.2.2.2 Rising healthcare costs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Advancements in genomic and proteomic technologies
                    5.2.3.2 Significant growth prospects in developing countries
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
                    5.2.4.2 Stringent regulatory frameworks
    5.3 IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET
    5.4 PRICING ANALYSIS
           TABLE 1 PRICES OF INFLUENZA DIAGNOSTIC PRODUCTS (2021)
    5.5 PATENT ANALYSIS
    5.6 TRADE ANALYSIS
           5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
                     TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 20 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASES
    5.8 SUPPLY CHAIN ANALYSIS
           FIGURE 21 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.9 ECOSYSTEM ANALYSIS OF THE INFLUENZA DIAGNOSTICS MARKET
           FIGURE 22 INFLUENZA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
           5.9.1 ROLE IN THE ECOSYSTEM
    5.10 PORTER’S FIVE FORCES ANALYSIS
           TABLE 4 INFLUENZA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT FROM NEW ENTRANTS
           5.10.2 THREAT FROM SUBSTITUTES
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 BARGAINING POWER OF SUPPLIERS
           5.10.5 DEGREE OF COMPETITION
    5.11 PESTLE ANALYSIS
    5.12 REGULATORY LANDSCAPE
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 Canada
           5.12.2 EUROPE
           5.12.3 ASIA PACIFIC
                    5.12.3.1 Japan
                    5.12.3.2 India
                    5.12.3.3 China
           5.12.4 LATIN AMERICA
                    5.12.4.1 Brazil
                    5.12.4.2 Mexico
           5.12.5 MIDDLE EAST
           5.12.6 AFRICA
    5.13 TECHNOLOGY ANALYSIS
    5.14 DISRUPTIVE TECHNOLOGIES IN THE INFLUENZA DIAGNOSTICS MARKET
           5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE INFLUENZA DIAGNOSTICS MARKET
                     FIGURE 23 REVENUE SHIFT FOR THE INFLUENZA DIAGNOSTICS MARKET

6 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 70)
    6.1 INTRODUCTION
           TABLE 5 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 TEST KITS & REAGENTS
           6.2.1 REPEAT PURCHASE OF TEST KITS & REAGENTS TO DRIVE MARKET GROWTH IN THE COMING YEARS
                    FIGURE 24 INSIGHTS FROM INDUSTRY EXPERTS ON TEST KITS & REAGENTS
                    TABLE 6 INFLUENZA DIAGNOSTICS MARKET FOR TEST KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO PROPEL MARKET GROWTH
                    TABLE 7 KEY INSTRUMENTS IN THE INFLUENZA DIAGNOSTICS MARKET
                    TABLE 8 INFLUENZA DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
    6.4 OTHER PRODUCTS
           TABLE 9 INFLUENZA DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2019–2026 (USD MILLION)

7 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 76)
    7.1 INTRODUCTION
           TABLE 10 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
    7.2 MOLECULAR DIAGNOSTIC TESTS
           TABLE 11 MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 12 MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,2019–2026 (USD MILLION)
           7.2.1 POLYMERASE CHAIN REACTION TESTS
                    7.2.1.1 Ability of PCR tests to distinguish between influenza A and B viruses is driving its adoption in clinical settings
                               TABLE 13 POLYMERASE CHAIN REACTION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS
                    TABLE 14 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 15 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.1 Transcription-mediated amplification-based assays
                               7.2.2.1.1 Wide application range in pathogen detection to drive the market growth
                                            TABLE 16 TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.2 Loop-mediated isothermal amplification-based assays
                               7.2.2.2.1 Rapidity, stability, and sensitivity have driven the use of loop-mediated isothermal amplification-based assays
                                            TABLE 17 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS MARKET,BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.3 Nucleic acid sequence-based amplification assays
                               7.2.2.3.1 Nucleic acid sequence-based amplification assays are preferred in hospitals and clinical settings as they reduce the need for additional reverse transcription steps
                                             TABLE 18 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.4 Other isothermal nucleic acid amplification tests
                               TABLE 19 OTHER ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.2.3 OTHER MOLECULAR DIAGNOSTIC TESTS
                    TABLE 20 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 TRADITIONAL DIAGNOSTIC TESTS
           TABLE 21 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 22 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.1 RAPID INFLUENZA DIAGNOSTIC TESTS
                    7.3.1.1 Rapid influenza diagnostic tests are widely used due to their ease of use and rapid interpretability of results
                               TABLE 23 RAPID INFLUENZA DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.2 VIRAL CULTURE TESTS
                    7.3.2.1 Wide use of viral cultures as confirmatory tests to ensure the results of RIDTs to drive market growth
                               TABLE 24 VIRAL CULTURE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.3 DIRECT FLUORESCENT ANTIBODY TESTS
                    7.3.3.1 Adoption of DFA tests is increasing due to their higher sensitivity compared to RIDTs
                               TABLE 25 DIRECT FLUORESCENT ANTIBODY TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.4 SEROLOGICAL TESTS
                    7.3.4.1 Development of lab-on-chip-based multiplex assays to support market growth
                               TABLE 26 SEROLOGICAL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

8 INFLUENZA DIAGNOSTICS MARKET, BY END USER (Page No. - 89)
    8.1 INTRODUCTION
           TABLE 27 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.2 DIAGNOSTIC LABORATORIES
           8.2.1 LARGE NUMBER OF INFLUENZA DIAGNOSTIC TESTS PERFORMED IN DIAGNOSTIC LABORATORIES TO DRIVE MARKET GROWTH
                    TABLE 28 INFLUENZA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
    8.3 HOSPITALS & CLINICS
           8.3.1 GROWING GLOBAL NUMBER OF HOSPITALS DUE TO INCREASING INFECTIOUS DISEASE INCIDENCE TO DRIVE MARKET GROWTH
                    TABLE 29 INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019–2026 (USD MILLION)
    8.4 OTHER END USERS
           TABLE 30 INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

9 INFLUENZA DIAGNOSTICS MARKET, BY REGION (Page No. - 93)
    9.1 INTRODUCTION
           TABLE 31 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 32 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
    9.2 NORTH AMERICA
           FIGURE 25 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
           TABLE 33 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 34 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 35 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
           TABLE 36 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 37 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 38 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 39 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,2019–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Technological advancements in influenza diagnostics to favor market growth in the US
                               TABLE 40 US: PRODUCT APPROVALS IN THE INFLUENZA DIAGNOSTICS MARKET
                               TABLE 41 US: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 42 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 43 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 44 US: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 45 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 46 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Government initiatives for developing diagnostic techniques to support market growth in Canada
                               TABLE 47 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 48 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 49 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 50 CANADA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 51 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 52 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 53 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,2019–2026 (USD MILLION)
           TABLE 54 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 55 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
           TABLE 56 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 57 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 58 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 59 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Increasing demand for technologically advanced diagnostic techniques to drive market growth in Germany
                               TABLE 60 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 61 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 62 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 63 GERMANY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 64 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 65 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.2 ITALY
                    9.3.2.1 Well-developed healthcare system in Italy to drive the adoption of advanced diagnostic technologies
                               TABLE 66 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 67 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 68 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 69 ITALY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 70 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 71 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 High healthcare expenditure by the government to drive market growth in France
                               TABLE 72 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 73 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 74 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 75 FRANCE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 76 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 77 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.4 SPAIN
                    9.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth in Spain
                               TABLE 78 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 79 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 80 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 81 SPAIN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 82 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 83 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.5 UK
                    9.3.5.1 Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market
                               TABLE 84 UK: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 85 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 86 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 87 UK: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 88 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 89 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 90 ROE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 91 ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 92 ROE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 93 ROE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 94 ROE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 95 ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 26 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
           TABLE 96 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 97 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 98 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
           TABLE 99 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 100 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 101 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 102 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing investments by government agencies to drive market growth in China
                               TABLE 103 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 104 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 105 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 106 CHINA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 107 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 108 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
                               TABLE 109 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 110 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 111 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 112 JAPAN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 113 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,2019–2026 (USD MILLION)
                               TABLE 114 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Increase in public and private investments in the country’s healthcare system will drive market growth
                               TABLE 115 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 116 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                               TABLE 117 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 118 INDIA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 119 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 120 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 121 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 122 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 123 ROAPAC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 124 ROAPAC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 125 ROAPAC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 126 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.5 LATIN AMERICA
           9.5.1 RISING DISEASE PREVALENCE AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE LATAM MARKET
                    TABLE 127 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 128 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 129 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 130 LATIN AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 131 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 132 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH
                    TABLE 133 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 134 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 136 MIDDLE EAST & AFRICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 137 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 138 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 139)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET
                        TABLE 139 STRATEGIES ADOPTED BY KEY INFLUENZA DIAGNOSTIC PRODUCT MANUFACTURING COMPANIES
     10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 27 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET
     10.4 MARKET SHARE ANALYSIS
             FIGURE 28 INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
             TABLE 140 INFLUENZA DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 29 INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
     10.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 30 INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     10.7 COMPETITIVE BENCHMARKING
             FIGURE 31 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET
             TABLE 141 COMPANY PRODUCT FOOTPRINT
             TABLE 142 COMPANY REGIONAL FOOTPRINT
     10.8 COMPETITIVE SCENARIO
             10.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 143 KEY PRODUCT LAUNCHES & APPROVALS
             10.8.2 DEALS
                        TABLE 144 KEY DEALS

11 COMPANY PROFILES (Page No. - 150)
     11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
             11.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 145 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             11.1.2 BECTON, DICKINSON AND COMPANY
                        TABLE 146 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             11.1.3 F. HOFFMANN-LA ROCHE AG
                        TABLE 147 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             11.1.4 HOLOGIC, INC.
                        TABLE 148 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 35 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
             11.1.5 ABBOTT LABORATORIES, INC.
                        TABLE 149 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 36 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             11.1.6 DANAHER CORPORATION
                        TABLE 150 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.7 QUIDEL CORPORATION
                        TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 38 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.8 SIEMENS HEALTHINEERS
                        TABLE 152 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
             11.1.9 BIOMÉRIEUX SA
                        TABLE 153 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 40 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
             11.1.10 MERIDIAN BIOSCIENCE
                        TABLE 154 MERIDIAN BIOSCIENCE: BUSINESS OVERVIEW
                        FIGURE 41 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2020)
     11.2 OTHER PLAYERS
             11.2.1 GENMARK DIAGNOSTICS, INC.
             11.2.2 LUMINEX CORPORATION
             11.2.3 TECAN TRADING AG
             11.2.4 DIASORIN SA
             11.2.5 ALTONA DIAGNOSTICS GMBH
             11.2.6 SEKISUI DIAGNOSTICS
             11.2.7 SA SCIENTIFIC, LTD.
             11.2.8 CORIS BIOCONCEPT SPRL
             11.2.9 ELITECH GROUP
             11.2.10 MAST GROUP LTD.
             11.2.11 GENOME DIAGNOSTICS PVT. LTD.
             11.2.12 GERMAINE LABORATORIES, INC.
             11.2.13 RESPONSE BIOMEDICAL CORP.
             11.2.14 TAUNS LABORATORIES, INC.
             11.2.15 3B BLACKBIO BIOTECH INDIA LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

12 APPENDIX (Page No. - 187)
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
     12.2 DISCUSSION GUIDE
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 AVAILABLE CUSTOMIZATIONS
     12.5 RELATED REPORTS
     12.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the influenza diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

Influenza Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the influenza diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the influenza diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Influenza Diagnostics Market Size: Top-Down Approach

Influenza Diagnostics Market Size, and Top-Down Approach

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the influenza diagnostics market by product, test type, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges).
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa,
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2.
  • To track and analyze company developments such as acquisition, approval and product launch in the influenza diagnostics market.
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Influenza diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa.

Company profiles

  • Product portfolio matrix for leading market players.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Influenza Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Influenza Diagnostics Market

Request For Special Pricing
Report Code
MD 7514
Published ON
Sep, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Influenza Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved